EATRIS is the infrastructure for translational research, focusing on developing scientific discoveries into healthcare interventions. Translational research is highly inter-disciplinary, utilising advanced analytical technologies, clinical insights and regulatory compliant research execution to support robust validation of disease pathology and the development of new ways to diagnose and treat disease. A key feature of the EATRIS approach is ensuring patient co-creation at all steps of the development process, to ensure that clinical application is the goal at all times. Through its distributed infrastructure, which comprises over 150 leading research institutions in fourteen European countries (Bulgaria, Croatia, Czech Republic, Finland, France, Italy, Latvia, Netherlands, Norway, Portugal, Slovenia, Spain and Sweden) EATRIS supports both public and private research entities. The EATRIS Scientific Platforms (Biomarkers, Small Molecules, Imaging and Tracing, Advanced Therapy Medicinal Products (ATMPs), and Vaccines, Inflammation and Immune Monitoring) represent and structure the scientific and technology offering of the RI. The EATRIS scientific platforms are composed of academic and non-profit research institutions in biomedical translational research. All members possess well-established track records in entering clinical development, hosting unique infrastructures, licenses (such as Good Manufacturing Practice (GMP) laboratories), and clinical expertise with access to a broad array of patient cohorts. Each platform offers a specific set of infrastructure services targeted to the needs of its users (industry, academia, charity funders and governments). Biologists and clinical researchers work together using cutting-edge analytical platforms and innovative clinical models to gain a deep understanding of the biological process underlying a disease, and the mechanism by which a therapeutic may have an effect. EATRIS facilitates the interdisciplinary team science approach essential to successful translation, by bringing together laboratory, clinical, industrial, legal and regulatory expertise. Additionally, EATRIS institutes collaborate to overcome bottlenecks in translational research, for instance by undertaking standardisation and best practice exchange. EATRIS contributes to the development of biomedical sciences in the European Research Area providing Europe with a comprehensive Research Infrastructure helping to respond to challenges in science, industry and society and enable researchers to address societal challenges with a global dimension. EATRIS leading efforts can be illustrated with few examples of projects and initiatives such as Translation Together, a unique collaboration of leading translational research organisations from around the world with EATRIS being one of the original founders; EATRIS participation in IMI projects EU-PEARL and TRUSTroke or UMBRELLA as key partner leading the sustainability strategy; Glaxosmithkline (GSK) Imaging hub, developed and managed by EATRIS for GSK (large pharma) to deliver a clinical and scientific network for the development and application of innovative imaging methods for inflammatory diseases. Additionally, EATRIS coordinates REMEDi4ALL, an ambitious EU-funded research initiative focusing on repurposing medicines across Europe.